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e thank Drs. Roberts and Hare for their interest in our paper
escribing cardiovascular outcomes among JUPITER (Justification
or the Use of statins in Primary prevention: an Intervention Trial
valuating Rosuvastatin) participants classified according to their
aseline renal function status. We agree that there are limitations
f the Modification of Diet and Renal Disease equation for
stimating glomerular filtration rate (GFR) and that our analysis
as based on the Modification of Diet and Renal Disease estimate
f GFR using a single baseline serum creatinine level. We also
cknowledge that the variability of serum creatinine can influence
stimated glomerular filtration rate (eGFR), particularly among
ndividuals with lower serum creatinine levels. Recognizing these
imitations, we confirmed that most (81%) of the JUPITER study
articipants who had an eGFR 60 ml/min/1.73 m2 at baseline had
n eGFR60ml/min/1.73m2 on repeat assessments performed after
2 months of randomized treatment with either rosuvastatin 20 mg or
lacebo. Although the distribution of age, sex, and race among
UPITER participants with an eGFR60 ml/min/1.73 m2 may not
e representative of chronic kidney disease patients encountered by
ephrologists in clinical practice, we believe that our finding thatiddle-age and older adults who had high-sensitivity C-reactive
rotein2.0 mg/l and an eGFR60 ml/min/1.73 m2 experienced a
5% decrease in the risk of major cardiovascular events during
reatment with rosuvastatin 20 mg to be clinically relevant (1).
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